OncoGenex Pharmaceuticals Inc.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. Product candidates are being developed to block the production of specific proteins associated with the development of treatment resistance, which OncoGenex believes will increase survival time and improve the quality of life for cancer patients.
Research Corporation Technologies invested in OncoGenex through Milestone Medica Corporation (MMC) in Canada. RBC Technology Ventures and RCT created MMC in 1998 to invest in product development opportunities derived from Canadian biomedical research. MMC is now fully invested and has been assisting its investee companies to reach their financial and technical milestones.
Inventor/Founder
Martin Gleave, Ph.D., University of British Columbia